Searchable abstracts of presentations at key conferences in endocrinology

ea0038fp1 | (1) | SFEBES2015

Inhibition of NFAT signalling in vivo improves microvascular endothelial function in a mouse model of chronic diabetes

McNeilly Alison , Garcia-Vaz Eliana , Gallagher Jennifer , McCrimmon Rory , Gomez Maria , Khan Faisel

Vascular disease is a major cause of morbidity and mortality in people who have diabetes. Hyperglycaemia is associated with increased transcriptional activity of nuclear factor of activated T cells (NFAT) in the vasculature. NFAT activation enhances expression of pro-inflammatory mediators including osteopontin, COX2 and IL6, implicated in the development of vascular disease. This study investigated the therapeutic potential of NFAT inhibition on the progression of microvascul...

ea0070oc3.3 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Circulating follistatin predicts type 2 diabetes risk

Wu Chuanyan , Borné Yan , Gao Rui , López Rodriguez Maykel , Roell William , Wilson Jonathan , Ahlqvist Emma , Luan Cheng , Peter Andreas , Machann Jürgen , Hong Mun-Gwan , Schwenk Jochen , Nilsson Peter , Shore Angela , Khan Faisel , Natali Andrea , Melander Olle , Orho-Melander Marju , Nilsson Jan , Renström Erik , Wollheim Claes , Pearson Ewan , Franks Paul , White Morris , Duffin Kevin , Vaag Allan , Laakso Markku , Stefan Norbert , Groop Leif , De Marinis Yang

Follistatin is a hepatokine found to be elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. We report that elevated baseline circulating follistatin levels predict future T2D incidence in longitudinal cohorts including up to 5274 individuals. Individuals with elevated circulating follistatin had higher risk of developing type 2 diabetes during follow-up of 4 years (IMI-DIRECT-METSIM, n = 1079, Finland), 5 and 19 years (MDC-CC, n...